The pooled hazard ratio along with the 95% confidence interval for the association between low B2M expression and overall survival in 1921 cases of glioma patients was 0.43 (0.35–0.54), with no significant heterogeneity among the three datasets(Figure 5B). The gene discussed is B2M; the disease is central nervous system cancer.